Mr. Speaker, my question is for the Minister of Health. The Food and Drug Administration has authorized the marketing of a drug, 3TC, in the U.S. before Canada has authorized it, although they both received applications at the same time and although the drug was discovered in Quebec, at Laval. Worse still, in both the U.S. and Canada, examination of the drug submission was fast tracked.
How can the minister explain that fast tracking of drugs moves faster in the United States than in Canada, and that the Canadian fast track looks more like a secondary road than a super highway?